Chemistry:Sodelglitazar
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C23H21F4NO3S2 |
| Molar mass | 499.54 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Sodelglitazar, formerly known as GW 677954, is a thiazole PPARδ receptor agonist developed by GlaxoSmithKline.[2] While it is primarily active at the PPARδ receptor, it is considered a pan agonist with activity at PPARα and PPARγ receptors.[3]
Safety
Phase 2 studies were terminated prior to completion due to safety findings in rodent studies.[4]
See also
References
- ↑ Rodolfo C, Marie GR, Hurst III LM, Lawrence SM, "Thiazole derivatives for treating ppar related disorders", US patent abandoned 7105551, published 1 April 2004, assigned to SmithKlineBeecham
- ↑ "Docking and molecular dynamics simulations of peroxisome proliferator activated receptors interacting with pan agonist sodelglitazar". Protein and Peptide Letters 18 (10): 1021–7. October 2011. doi:10.2174/092986611796378701. PMID 21592078.
- ↑ Nuclear Receptors as Drug Targets. Wiley. 2008. pp. 380–. ISBN 978-3-527-31872-8. https://books.google.com/books?id=iATfLbPgRugC&pg=PA380. Retrieved 2 April 2013.
- ↑ "A randomised, double-blind, parallel group, placebo-controlled, multicentre study to evaluate the safety, tolerability and efficacy of oral GW677954 capsules 2.5mg, 5mg, 10mg and 20mg a day for 24 weeks in overweight dyslipidaemic subjects". GlaxoSmithKline. 2013-09-01. http://download.gsk-clinicalstudyregister.com/files/20459.pdf.
 |  |
